Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD

William E. Pelham, Lisa Burrows-MacLean, Elizabeth M. Gnagy, Gregory A. Fabiano, Erika K. Coles, Katy E. Tresco, Anil Chacko, Brian T. Wymbs, Amber L. Wienke, Kathryn S. Walker, Martin T. Hoffman

Research output: Contribution to journalArticle

Abstract

Stimulant medication and behavioral treatments are evidence-based for children with attention-deficit/hyperactivity disorder, but the combination of the 2 treatments has been understudied. In this investigation, methylphenidate (MPH) was crossed with 2 levels of behavior modification (BMOD) in a summer treatment program. Twenty-seven children with attention-deficit/hyperactivity disorder, aged 6-12, participated. Children received placebo and 3 doses of transdermal MPH (12.5 cm2, 25.0 cm2, and 37.5 cm 2). BMOD was implemented on alternating weeks. Both treatments produced large and significant effects. Combined treatment was superior to either treatment alone. The effects of transdermal MPH were comparable to those found in this setting in previous studies with multiple stimulant medications and formulations. Consistent with other research, low doses of MPH-even lower than in previous studies-yielded enhanced effects in combination with behavior modification.

Original languageEnglish (US)
Pages (from-to)111-126
Number of pages16
JournalExperimental and Clinical Psychopharmacology
Volume13
Issue number2
DOIs
StatePublished - May 2005

Fingerprint

Methylphenidate
Behavior Therapy
Attention Deficit Disorder with Hyperactivity
Therapeutics
Placebos
Research

Keywords

  • Attention deficit hyperactivity disorder
  • Behavioral treatment
  • Combined treatment
  • Methylphenidate

ASJC Scopus subject areas

  • Pharmacology
  • Experimental and Cognitive Psychology

Cite this

Pelham, W. E., Burrows-MacLean, L., Gnagy, E. M., Fabiano, G. A., Coles, E. K., Tresco, K. E., ... Hoffman, M. T. (2005). Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Experimental and Clinical Psychopharmacology, 13(2), 111-126. https://doi.org/10.1037/1064-1297.13.2.111

Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. / Pelham, William E.; Burrows-MacLean, Lisa; Gnagy, Elizabeth M.; Fabiano, Gregory A.; Coles, Erika K.; Tresco, Katy E.; Chacko, Anil; Wymbs, Brian T.; Wienke, Amber L.; Walker, Kathryn S.; Hoffman, Martin T.

In: Experimental and Clinical Psychopharmacology, Vol. 13, No. 2, 05.2005, p. 111-126.

Research output: Contribution to journalArticle

Pelham, WE, Burrows-MacLean, L, Gnagy, EM, Fabiano, GA, Coles, EK, Tresco, KE, Chacko, A, Wymbs, BT, Wienke, AL, Walker, KS & Hoffman, MT 2005, 'Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD', Experimental and Clinical Psychopharmacology, vol. 13, no. 2, pp. 111-126. https://doi.org/10.1037/1064-1297.13.2.111
Pelham, William E. ; Burrows-MacLean, Lisa ; Gnagy, Elizabeth M. ; Fabiano, Gregory A. ; Coles, Erika K. ; Tresco, Katy E. ; Chacko, Anil ; Wymbs, Brian T. ; Wienke, Amber L. ; Walker, Kathryn S. ; Hoffman, Martin T. / Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. In: Experimental and Clinical Psychopharmacology. 2005 ; Vol. 13, No. 2. pp. 111-126.
@article{0b787f8f37214cdf80221d480a674790,
title = "Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD",
abstract = "Stimulant medication and behavioral treatments are evidence-based for children with attention-deficit/hyperactivity disorder, but the combination of the 2 treatments has been understudied. In this investigation, methylphenidate (MPH) was crossed with 2 levels of behavior modification (BMOD) in a summer treatment program. Twenty-seven children with attention-deficit/hyperactivity disorder, aged 6-12, participated. Children received placebo and 3 doses of transdermal MPH (12.5 cm2, 25.0 cm2, and 37.5 cm 2). BMOD was implemented on alternating weeks. Both treatments produced large and significant effects. Combined treatment was superior to either treatment alone. The effects of transdermal MPH were comparable to those found in this setting in previous studies with multiple stimulant medications and formulations. Consistent with other research, low doses of MPH-even lower than in previous studies-yielded enhanced effects in combination with behavior modification.",
keywords = "Attention deficit hyperactivity disorder, Behavioral treatment, Combined treatment, Methylphenidate",
author = "Pelham, {William E.} and Lisa Burrows-MacLean and Gnagy, {Elizabeth M.} and Fabiano, {Gregory A.} and Coles, {Erika K.} and Tresco, {Katy E.} and Anil Chacko and Wymbs, {Brian T.} and Wienke, {Amber L.} and Walker, {Kathryn S.} and Hoffman, {Martin T.}",
year = "2005",
month = "5",
doi = "10.1037/1064-1297.13.2.111",
language = "English (US)",
volume = "13",
pages = "111--126",
journal = "Experimental and Clinical Psychopharmacology",
issn = "1064-1297",
publisher = "American Psychological Association Inc.",
number = "2",

}

TY - JOUR

T1 - Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD

AU - Pelham, William E.

AU - Burrows-MacLean, Lisa

AU - Gnagy, Elizabeth M.

AU - Fabiano, Gregory A.

AU - Coles, Erika K.

AU - Tresco, Katy E.

AU - Chacko, Anil

AU - Wymbs, Brian T.

AU - Wienke, Amber L.

AU - Walker, Kathryn S.

AU - Hoffman, Martin T.

PY - 2005/5

Y1 - 2005/5

N2 - Stimulant medication and behavioral treatments are evidence-based for children with attention-deficit/hyperactivity disorder, but the combination of the 2 treatments has been understudied. In this investigation, methylphenidate (MPH) was crossed with 2 levels of behavior modification (BMOD) in a summer treatment program. Twenty-seven children with attention-deficit/hyperactivity disorder, aged 6-12, participated. Children received placebo and 3 doses of transdermal MPH (12.5 cm2, 25.0 cm2, and 37.5 cm 2). BMOD was implemented on alternating weeks. Both treatments produced large and significant effects. Combined treatment was superior to either treatment alone. The effects of transdermal MPH were comparable to those found in this setting in previous studies with multiple stimulant medications and formulations. Consistent with other research, low doses of MPH-even lower than in previous studies-yielded enhanced effects in combination with behavior modification.

AB - Stimulant medication and behavioral treatments are evidence-based for children with attention-deficit/hyperactivity disorder, but the combination of the 2 treatments has been understudied. In this investigation, methylphenidate (MPH) was crossed with 2 levels of behavior modification (BMOD) in a summer treatment program. Twenty-seven children with attention-deficit/hyperactivity disorder, aged 6-12, participated. Children received placebo and 3 doses of transdermal MPH (12.5 cm2, 25.0 cm2, and 37.5 cm 2). BMOD was implemented on alternating weeks. Both treatments produced large and significant effects. Combined treatment was superior to either treatment alone. The effects of transdermal MPH were comparable to those found in this setting in previous studies with multiple stimulant medications and formulations. Consistent with other research, low doses of MPH-even lower than in previous studies-yielded enhanced effects in combination with behavior modification.

KW - Attention deficit hyperactivity disorder

KW - Behavioral treatment

KW - Combined treatment

KW - Methylphenidate

UR - http://www.scopus.com/inward/record.url?scp=20344375922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20344375922&partnerID=8YFLogxK

U2 - 10.1037/1064-1297.13.2.111

DO - 10.1037/1064-1297.13.2.111

M3 - Article

VL - 13

SP - 111

EP - 126

JO - Experimental and Clinical Psychopharmacology

JF - Experimental and Clinical Psychopharmacology

SN - 1064-1297

IS - 2

ER -